Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Despite FDA Recommendation for Postmarketing Surveillance, Amgen's Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis
Despite FDA Recommendation for Postmarketing Surveillance, Amgen's Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis
Despite FDA Recommendation for Postmarketing Surveillance, Amgen's Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis
Submitted by
admin
on January 9, 2010 - 12:48pm
Source:
Trading Markets
News Tags:
Prolia
osteoporosis
Amgen
Headline:
Despite FDA Recommendation for Postmarketing Surveillance, Amgen's Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis
Do Not Allow Advertisers to Use My Personal information